Professor, Surgery, University of Florida College of Medicine
General Surgery
Dr. Mark S. Roh, MD
|
|
Give Review
Doctor Mark S. Roh, MD is an expert in the field of General Surgery. He graduated from The Ohio State University College of Medicine. He received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Pittsburgh Magazine" and "Fellow (FACS)". Doctor Mark S. Roh, MD is also published. He has 50 publications published. The lastest publication: "Effect of tuftsin on human Kupffer cell.' Mark accepts Medicare payments and is listed with Medicare.gov.
Publications
- Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
- Clinical features of drug-induced hypersensitivity syndrome in 38 patients.
- Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal Cancer: a North Central Cancer Treatment Group (NCCTG)/ National...
- State of the Journal 2010: managing growth, extending our reach--now the official journal for the Society of Surgical Oncology and the American Society of Breast Surge...
- Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
- Syndecan-1 expression in gallbladder Cancer and its prognostic significance.
- Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of Liver function, portal vein embolization, and resec...
- Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric Cancer.
- Improving resectability of hepatic coloRectal metastases: expert consensus statement by Abdalla et al.
- OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal Cancer.
- Staging of hepatocellular carcinoma.
- Staging classifications for hepatocellular carcinoma.
- Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma.
- Long-term survival after an aggressive surgical approach in patients with breast Cancer hepatic metastases.
- Critical evaluation of the different staging systems for hepatocellular carcinoma (Br J Surg 2004; 91: 400-408).
- Utility of intraoperative Liver ultrasound.
- Expanding the indications for hepatic resection in patients with coloRectal liver metastases.
- The presence of coloRectal hepatic metastases does not preclude pulmonary metastasectomy.
- Annals of surgical oncology impact factor/rating has dramatically increased.
- Should a potentially noncurative resection that prolongs survival be offered to patients with coloRectal liver metastases?
- Results of surgical resection for hepatocellular carcinoma.
- Increasing the number of patients undergoing resection of coloRectal liver metastases.
- Surgery after downstaging of unresectable hepatic Tumors with intra-arterial chemotherapy.
- Intraoperative radiofrequency ablation or cryoablation for hepatic Malignancies.
- Extending the indications for hepatic resection.
- Effect of tuftsin on human Kupffer cell.
- Repeat hepatic resection as effective treatment of recurrent coloRectal liver metastases.
- Prognostic factors in surgical resection for hepatocellular carcinoma.
- Improved survival after resection of coloRectal liver metastases.
- Perineal reconstruction using single gracilis myocutaneous flaps.
- Stimulation of phagocytic activity of murine Kupffer cells by tuftsin.
- Surgical management of hepatoma.
- Adjuvant hepatic arterial infusion chemotherapy after curative resection of coloRectal liver metastases.
- Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices.
- Mechanisms of Kupffer cell cytotoxicity in vitro against the syngeneic murine colon adenocarcinoma line MCA26.
- Arterial complications from long-term hepatic artery chemoinfusion catheters: evaluation with CT.
- Increase in activity and level of pp60c-src in progressive stages of human colorectal Cancer.
- Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of coloRectal liver metastases.
- Current strategies for the treatment of hepatocellular carcinoma.
- Recent progress in the treatment of hepatocellular carcinoma.
- Human Kupffer cells are cytotoxic against human colon adenocarcinoma.
- Human recombinant macrophage colony stimulating factor activates murine Kupffer cells to a cytotoxic state.
- Advances in the detection and treatment of coloRectal carcinoma.
- Hepatic artery infusion pumps: cannulation techniques and other surgical considerations.
- Hepatic resection for coloRectal liver metastases.
- Surgical therapy of early Rectal carcinoma.
- Stimulatory effect of interleukin-1 upon hepatic metabolism.
- Elevated energy expenditure in hepatocytes from tumor-bearing rats.
- Gluconeogenesis in tumor-influenced hepatocytes.
Schools
The Ohio State University College Of Medicine
University Health Center
University Of Pittsburgh Medical Center
Memorial SloanKettering Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Surgical Oncology
- General Surgery
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Pittsburgh Magazine
- Fellow (FACS)
Education
-
University of Southern California -
Memorial Sloan-Kettering Cancer Center -
University of Pittsburgh Medical Center -
The Ohio State University College of Medicine
Hospital
-
Orlando Regional Medical Center
Drug Facts
| NPI NUMBER | 1871594143 | |
| NPPES Provider LastName | ROH | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 328062134 | |
| NPPES Provider State | FL | |
| Specialty Description | Surgical Oncology | |
| Total Claim Count | 20.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871594143 |
| Last Name Of The Provider | ROH |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Florencio Ello, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Debashish Bose, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc L. Demers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajesh M. Nair, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manuel R. Perez-Izquierdo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patricio B. Quijada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bobby L. Gibbons II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua G. Corsa, MD |